Table 3– Hospitalisations for adverse events related to combined chemoradiotherapy (CRT) and radiation therapy (RT) among unresected stage I and II lung cancer patients in the study
ToxicityPatients hospitalised with toxicity-related diagnosesOR (95% CI)#OR (95% CI) adjusted for propensity scores
RT aloneCRT
Infection104 (4.8)73 (8.7)1.9 (1.4–2.6)2.0 (1.4–2.8)
Neutropenia≤11(<0.5)>50 (>5.5)24.6 (10.5–57.3)21.5 (9.0–51.4)
Fever12 (0.6)12 (1.4)2.6 (1.2–5.8)2.1 (0.9–5.2)
Dehydration132 (6.1)92 (10.9)1.9 (1.4–2.5)1.8 (1.4–2.5)
Nausea/emesis19 (0.9)25 (3.0)3.4 (1.9–6.3)3.1 (1.6–5.8)
Anaemia105 (4.8)108 (12.8)2.9 (2.2–3.8)2.8 (2.1–3.9)
Thrombocytopenia≤11 (<0.5)≤11 (<1.0)6.9 (1.8–26.0)11.5 (2.9–45.7)
Renal dysfunction22 (1.0)13 (1.5)1.5 (0.7–3.0)1.6 (0.8–3.4)
Unspecified adverse events
of systemic therapy
≤11 (<0.5)<15 (<2.0)36.5 (4.8–277.6)30.8 (3.9–243.4)
  • Data are presented as n (%), unless otherwise stated. #: odds ratio for toxicity-related hospitalisation among patients treated with CRT compared with those treated with RT alone; : because of Surveillance, Epidemiology and End Results registry linked to Medicare claims privacy rules, exact numbers are not reported for small subgroups, which might risk loss of confidentiality.